^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    S-588210

    i
    Associations
    News

    Trials

    Company:
    OncoTherapy, Shionogi, University of Chicago
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE) (NCT04106115)
    Phase 1/2
    University College, London
    Recruiting
    Last update posted :
    12/04/2024
    Initiation :
    03/25/2022
    Primary completion :
    05/31/2025
    Completion :
    05/31/2029
    PD-L1
    |
    HLA-A*02:01 • HLA-A*02
    |
    Imfinzi (durvalumab) • S-588210
    A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy (NCT02661659)
    Phase 1
    University of Chicago
    Withdrawn
    Last update posted :
    05/14/2018
    Initiation :
    06/12/2016
    Primary completion :
    10/03/2017
    Completion :
    10/03/2017
    HLA-A
    |
    HLA-A*02
    |
    S-588210